Clal Biotechnology Industries Ltd. (CBI)
Hogi Tower
12 Abba Hillel Silver Street
Ramat Gan
52506
Tel: 972-03-612-1616
Website: http://www.cbi.co.il/Home
9 articles about Clal Biotechnology Industries Ltd. (CBI)
-
Cambridge, Massachusetts-based Neon Therapeutics is launching an initial public offering (IPO) of 6,250,000 shares of common stock at a price offering of $16 per share.
-
Clal Biotech Appoints Julian Adams, Ph.D. As Chief Science Officer And President
1/31/2017
-
Clal Biotech Opts Out of Re-Acquiring Andromeda from Hyperion After Phase III Diabetes Drug Tanks
10/7/2015
-
Hyperion Therapeutics Enters Into Completion Of Phase III Clinical Trial, Option And Mutual Release Agreement With Clal Biotechnology Industries And Yeda Research and Development Company Ltd.
2/17/2015
-
Hyperion Therapeutics, Clal Biotechnology Industries Resolve Dispute Over $570 Million Biotech Problem
10/7/2014
-
Clal Biotechnology Industries Release: Andromeda Announces That Further Data Analyses Support Primary Endpoint in Andromeda Biotech's Phase III Clinical Study
5/10/2012
-
Teva Pharmaceutical Industries Limited, Clal Biotechnology Industries Raises Stake in Diabetes Treatment Developer, Andromeda; Teva and Clal to Invest $17.5 Million
6/14/2010
-
Yissum Ltd., Pontifax, and Clal Biotechnology Industries Invest $9 Million in Avraham Pharmaceuticals Ltd. to Pursue a Phase IIb Clinical Trial of Ladostigil, a Novel Drug for Treatment of Alzheimer's Disease
4/14/2010
-
Arte Ventures And Clal Biotechnology Industries Introduce A New Model For Biotech Investment Management
3/26/2006